Veru (NASDAQ:VERU – Get Free Report) and Hero Technologies (OTCMKTS:HENC – Get Free Report) are both medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their dividends, risk, institutional ownership, earnings, profitability, valuation and analyst recommendations.
Profitability
This table compares Veru and Hero Technologies’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Veru | N/A | -83.63% | -55.90% |
| Hero Technologies | N/A | N/A | N/A |
Earnings and Valuation
This table compares Veru and Hero Technologies”s gross revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Veru | $16.89 million | 2.26 | -$22.73 million | ($1.26) | -1.89 |
| Hero Technologies | N/A | N/A | N/A | N/A | N/A |
Hero Technologies has lower revenue, but higher earnings than Veru.
Analyst Ratings
This is a breakdown of current ratings and price targets for Veru and Hero Technologies, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Veru | 1 | 0 | 3 | 0 | 2.50 |
| Hero Technologies | 0 | 0 | 0 | 0 | 0.00 |
Veru presently has a consensus price target of $22.50, suggesting a potential upside of 845.38%. Given Veru’s stronger consensus rating and higher possible upside, analysts clearly believe Veru is more favorable than Hero Technologies.
Institutional and Insider Ownership
47.2% of Veru shares are owned by institutional investors. 14.2% of Veru shares are owned by company insiders. Comparatively, 0.2% of Hero Technologies shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.
Volatility and Risk
Veru has a beta of -1.35, indicating that its stock price is 235% less volatile than the S&P 500. Comparatively, Hero Technologies has a beta of -0.11, indicating that its stock price is 111% less volatile than the S&P 500.
Summary
Veru beats Hero Technologies on 6 of the 9 factors compared between the two stocks.
About Veru
Veru Inc., a late clinical stage biopharmaceutical company, focuses on developing medicines for treatment of metabolic diseases, oncology, and acute respiratory distress syndrome (ARDS). Its marketed products comprise FC2 female condom for the dual protection against unplanned pregnancy and the transmission of sexually transmitted infections. The company’s development program includes enobosarm, a selective androgen receptor modulator for treatment of augment fat loss and to prevent muscle loss in sarcopenic obese and overweight elderly patients; Enobosarm, a selective androgen receptor modulator for the treatment of AR+ ER+ HER2- metastatic breast cancer; and sabizabulin, a microtubule disruptor for the treatment of hospitalized patients with viral lung infection on oxygen support who are at high risk for viral induced ARDS and death. The company was formerly known as The Female Health Company and changed its name to Veru Inc. in July 2017. Veru Inc. was incorporated in 1971 and is headquartered in Miami, Florida.
About Hero Technologies
Hero Technologies Inc. operates as an early-stage cannabis company. It focuses on the provision of BlackBox, an aeroponic cannabis cultivation system that provides optimal growing conditions to enhance photosynthesis and the cultivation of large flowering plants and create increased harvest efficiencies. The company also intends to offer cannabis genetic engineering farmland for medical and recreational cannabis cultivation, production, distribution, packaging, and retail operations, as well as for dispensaries. The company is based in Dover, Delaware.
Receive News & Ratings for Veru Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Veru and related companies with MarketBeat.com's FREE daily email newsletter.
